

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM475379

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
BioPharma Credit PLC		05/02/2018	Public Limited Company: UNITED KINGDOM
RECEIVING PARTY DATA			
Name:	Braintree Laboratories, Inc.		
Street Address:	60 Columbian Street West		
City:	Braintree		
State/Country:	MASSACHUSETTS		
Postal Code:	02185		
Entity Type:	Corporation: MASSACHUSETTS		
PROPERTY NUMBERS Total: 2			
Property Type	Number	Word Mark	
Serial Number:	87693451	OZMILAC	
Serial Number:	87693437	OZMOTOL	
CORRESPONDENCE DATA			
Fax Number:	3127069000		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	312-701-8623		
Email:	rassmus@mayerbrown.com, mdecember@mayerbrown.com		
Correspondent Name:	Richard Assmus		
Address Line 1:	P.O. Box 2828		
Address Line 4:	Chicago, ILLINOIS 60690-2828		
ATTORNEY DOCKET NUMBER:	17553669		
NAME OF SUBMITTER:	Richard M. Assmus		
SIGNATURE:	/RMA/		
DATE SIGNED:	05/24/2018		
Total Attachments: 3			
source=Limited Release of Security Interest in Trademarks#page1.tif			
source=Limited Release of Security Interest in Trademarks#page2.tif			
source=Limited Release of Security Interest in Trademarks#page3.tif			

CH \$65.00 87693451

LIMITED RELEASE OF SECURITY INTEREST IN TRADEMARKS

THIS LIMITED RELEASE OF SECURITY INTEREST IN TRADEMARKS (this "Limited Release") is made as of May 2, 2018 ("Effective Date") by and among BioPharma Credit PLC, a public limited company incorporated under the laws of England and Wales, as collateral agent (in such capacity, "Grantee"), Braintree Laboratories, Inc., a Massachusetts corporation with its principal office at 60 Columbian Street West, P.O. Box 850929, Braintree, MA 02185-0929 ("Grantor"), and Sebela BT Holdings, Inc., a Delaware corporation with its principal office at 645 Hembree Pkwy., Suite I, Roswell, GA 30076 ("Borrower").

WHEREAS, Borrower and Grantee are parties to that certain Loan Agreement dated as of April 20, 2018 (the "Loan Agreement"). Terms capitalized but not defined herein shall have the meanings assigned to such terms in the Loan Agreement;

WHEREAS, pursuant to the terms and conditions of that certain Guaranty and Security Agreement among Borrower, Grantor, Grantee and the other parties thereto, dated as of May 1, 2018, Grantor and Grantee entered into a Trademark Security Agreement (the "Trademark Security Agreement"), whereby Grantor granted to Grantee a continuing security interest in all of Grantor's right, title and interest in, to and under the Trademark Collateral (as defined in the Trademark Security Agreement), including, without limitation, the patents and patent applications set forth on Schedule A attached hereto (the "Subject Trademarks"), to secure the payment of all amounts owed by Grantor under the Loan Agreement; and

WHEREAS, in connection with the Group Restructuring, Grantor has assigned all of its right, title and interest in and to all of the Subject Trademarks to Borrower and Borrower has subsequently assigned the same to Sebela International Development Limited, a Bermuda company, effective as of the Effective Date.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Grantee hereby terminates, cancels and releases any and all security interests it has against the Subject Trademarks and only in the Subject Trademarks, and discharges, quit claims and relinquishes unto the Grantor (in each case without recourse and without any representation or warranty) any and all right, title and interest it has in and to the Subject Trademarks (and only the Subject Trademarks) under the Trademark Security Agreement.

Grantee shall, at Grantor's expense, take all further actions, and provide to Grantor, Grantor's successors, assigns or other legal representatives, all such cooperation and assistance (including, without limitation, the execution and delivery of any and all documents or other instruments), reasonably requested by Grantor to more fully and effectively effectuate the purposes of this Limited Release.

This Limited Release shall be governed by, and construed and interpreted in accordance with, the laws of the State of New York, without regard to any principles of conflicts of law that could require the application of the law of any other jurisdiction.


* * * * *

IN WITNESS WHEREOF, Grantee has caused this Limited Release to be executed by its duly authorized representative as of the Effective Date.

BIOPHARMA CREDIT PLC, as Collateral Agent

By: Pharmakon Advisors, LP,
its Investment Manager

By: Pharmakon Management I, LLC,
its General Manager

By: 
Name: Martin Friedman
Title: Principal

SCHEDULE A

SUBJECT TRADEMARKS

<u>Entity Name</u>	<u>Country</u>	<u>Title</u>	<u>Filing Date</u>	<u>File Status</u>	<u>Serial No.</u>	<u>Reg. No.</u>
Braintree Laboratories, Inc.	United States of America	OZMILAC	11/21/2017	Pending	87/693451	
Braintree Laboratories, Inc.	United States of America	OZMOTOL	11/21/2017	Pending	87/693437	